XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
U
U

UCB


समाचार

EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns

CORRECTED-BRIEF-EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns Corrects source of brief to European Medicines Agency, not Merck & Co Oct 4 (Reuters) - European Medicines Agency (EMA): EMA: HAS STARTED A REVIEW OF MEDICINES CONTAINING FINASTERIDE AND DUTASTERIDE FOLLOWING CONCERNS REGARDING SUICIDAL
U

UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis

BRIEF-UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis Sept 30 (Reuters) - Ucb SA UCB.BR : ANNOUNCES A HEAD-TO-HEAD STUDY EVALUATING BIMZELX[®]▼(BIMEKIZUMAB) VERSUS SKYRIZI® (RISANKIZUMAB) IN ACTIVE PSORIATIC ARTHRITIS STUDY UNDERSCORES UCB'S BELIEF IN BIMEKIZUMAB WITH TOP-LINE RESULTS EXPECTED IN 2026 Source text:
U

UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS

BRIEF-UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS Sept 27 (Reuters) - Ucb SA UCB.BR : ANNOUNCES LATE-BREAKING TWO-YEAR DATA FOR BIMZELX(BIMEKIZUMAB) IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA AT EADV 2024 CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH BIMEKIZUMAB OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WE
U

Biogen rises after lupus drug meets main goal of late-stage study

BUZZ-Biogen rises after lupus drug meets main goal of late-stage study ** Shares of drugmaker Biogen BIIB.O rise 2.1% to $200 premarket ** Co and partner UCB UCB.BR say their experimental lupus treatment met the main goal of a late-stage trial ** Cos say the drug, dapirolizumab pegol, when given along with other standard of care treatments, showed
B
U

UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol

BRIEF-UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol Sept 24 (Reuters) - UCB UCB.BR : UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS ARE INITIATING SECOND PHASE 3 STUDY IN 2024 PARTICIPANTS FROM PHOENYCS GO STUDY WILL CONTINUE TO BE FOLLOWED IN A L
B
U

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
A
B
G
U

UCB rises on further Bimzelx approvals in the US

BUZZ-UCB rises on further Bimzelx approvals in the US ** Shares in UCB UCB.BR rise 2.2% after the Belgian biopharmaceutical company said the U.S. FDA had approved further indications for its Bimzelx treatment ** Bimzelx gets green light for psoriatic arthritis, nonradiographic axial spondyloarthritis and axial spondyloarthritis, following similar d
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Asia Cement, McKesson Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Asia Cement (China)'s 0743.HK shareholders have rejected its majority owner's take-private offer, it said. nL4N3KD0SV ** Drug distributor McKesson MCK.N said it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core
N
S
U
M

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** UCB UCB.BR , a Belgian biopharmaceutical firm, said it would sell its Chinese neurology and allergy business to Singapore-based asset management group CBC and Abu Dhabi sovereign investor Mubadala for $680 million.
N
S
U

Belgium's UCB to sell China neurology, allergy business for $680 mln

UPDATE 2-Belgium's UCB to sell China neurology, allergy business for $680 mln Acquisition includes anti-allergy medicines Zyrtec and Xyzal Deal expected to close in fourth quarter UCB to focus on innovation and partnerships Adds context in paragraph 7, advisers in final paragraph By Geert De Clercq and Yantoultra Ngui PARIS/SINGAPORE, Aug 26 (Reuters) - UCB UCB.BR , a Belgian biopharmaceutical firm, said on Monday it would sell its Chinese neurology and allergy business to Singapore-based asset
U

Mubadala Co-Invests In UCB's Mature Business In China

BRIEF-Mubadala Co-Invests In UCB's Mature Business In China Aug 26 (Reuters) - MUBADALA INVESTMENT [RIC:RIC:MUDEV.UL]: MUBADALA CO-INVESTS IN UCB'S MATURE BUSINESS IN CHINA TO REINFORCE ITS LONG-TERM COMMITMENT TO ASIAN MARKET CO IN PARTNERSHIP WITH CBC GROUP ACQUIRED 100% OWNERSHIP IN CARVE-OUT OF UCB PHARMA'S MATURE BUSINESS IN CHINA Further comp
U

Belgium's UCB sells China neurology and allergy business for $680 million

Belgium's UCB sells China neurology and allergy business for $680 million PARIS, Aug 26 (Reuters) - Belgian biopharmaceutical group UCB said in a statement it had agreed to sell its neurology and allergy business in China to Asian healthcare-dedicated asset management group CBC and Abu Dhabi-based investment company Mubadala for an amount of $680 million.
U

UCB To Divest Its Neurology And Allergy Business In China

BRIEF-UCB To Divest Its Neurology And Allergy Business In China Aug 26 (Reuters) - UCB SA UCB.BR : UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC® UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC®, XYZAL® AND ZHUHAI M
U

Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine

BUZZ-Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** JP Morgan raises UCB UCB.BR to "overweight" from "neutral" as it sees the Belgian biotech firm's "superior growth profile" as "significantly" undervalued by the market; cites expected acceleration in Bimzelx growth ** Morgan Stanley downgrades Sonova SOON.S to "underweight" from "equal-weight", flagging the hearing aid maker's EV/EBITA valua
M
S
U
V
V

Admiral, UCB SA, Victrex

EUROPE RESEARCH ROUNDUP-Admiral, UCB SA, Victrex Aug 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral, UCB SA and Victrex, on Wednesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3,550p from 3,400p * Demant A/S DEMANT.CO : Morgan Stanley raises to overweight from underweight * UCB SA UCB.BR : JP Morgan raises to overweight from neutral * Victrex Plc VCTX.L : Jefferies raises to hold from underperform * Watki
A
A
C
H
I
M
N
R
S
S
U
V
V
A

AJ Bell, Avon Technologies, Hannover

EUROPE RESEARCH ROUNDUP-AJ Bell, Avon Technologies, Hannover Aug 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AJ Bell, Avon Technologies and Hannover on Tuesday. HIGHLIGHTS * AJ Bell Plc AJBA.L : Morgan Stanley raises target price to 316p from 284p * Avon Technologies Plc AVON.L : Barclays raises target price to 1450p from 1400p * Hannover Re HNRGn.DE : Morgan Stanley raises target price to EUR 254 from EUR 252 * UCB SA UCB.B
A
A
B
B
C
H
H
H
H
K
P
R
R
S
S
T
U
W
P
N

UCB drops to bottom of BEL 20 after KBC downgrade

BUZZ-UCB drops to bottom of BEL 20 after KBC downgrade ** Shares in UCB UCB.BR fall 2.7% to the bottom of Belgium's BEL 20 .BFX blue-chip index after KBC Securities downgrades the biotech firm to "hold" from "accumulate" ** KBC says the downgrade is primarily caused by the substantial increase in UCB's share price, which has risen 135% from its Nov
U

Crest Nicholson, JDE Peet's, L'Oreal

EUROPE RESEARCH ROUNDUP-Crest Nicholson, JDE Peet's, L'Oreal Aug 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Crest Nicholson Holdings, JDE Peet's and L'Oreal, on Wednesday. HIGHLIGHTS * A.P. Moller-Maersk MAERSKb.CO : Deutsche Bank cuts PT to DKK 9217 from DKK 9283 * British American Tobacco Plc BATS.L : Barclays raises target price to 3100p from 2650p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt cuts to hold from add *
A
B
C
C
D
E
E
E
H
J
L
N
R
S
S
T
U
U
U
A
E
F
P

UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®]

BRIEF-UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®] Aug 5 (Reuters) - Ucb SA UCB.BR : ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR 320 MG DEVICE PRESENTATIONS OF BIMZELX[®] PATIENTS REQUIRING A 320 MG DOSE OF BIMEKIZUMAB WILL NOW HAVE AN ALTERNATIVE SINGLE-INJECTION OPTION OF BOTH PRE-FILLED SYRINGE AND PRE-FILLED PEN Source
U

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T



स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।